JP2017515889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515889A5 JP2017515889A5 JP2017502920A JP2017502920A JP2017515889A5 JP 2017515889 A5 JP2017515889 A5 JP 2017515889A5 JP 2017502920 A JP2017502920 A JP 2017502920A JP 2017502920 A JP2017502920 A JP 2017502920A JP 2017515889 A5 JP2017515889 A5 JP 2017515889A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- mol
- liposome
- adjuvant formulation
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 58
- 239000002671 adjuvant Substances 0.000 claims description 32
- 239000002502 liposome Substances 0.000 claims description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 19
- 230000002163 immunogen Effects 0.000 claims description 16
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 16
- 229930182490 saponin Natural products 0.000 claims description 16
- 150000007949 saponins Chemical class 0.000 claims description 16
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 8
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 4
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- 239000000232 Lipid Bilayer Substances 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 102100021696 Syncytin-1 Human genes 0.000 claims description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 4
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 4
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000002691 unilamellar liposome Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970118P | 2014-03-25 | 2014-03-25 | |
| US61/970,118 | 2014-03-25 | ||
| PCT/US2015/022461 WO2015148648A1 (en) | 2014-03-25 | 2015-03-25 | Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515889A JP2017515889A (ja) | 2017-06-15 |
| JP2017515889A5 true JP2017515889A5 (enExample) | 2018-05-10 |
| JP6608422B2 JP6608422B2 (ja) | 2019-11-20 |
Family
ID=52829375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502920A Active JP6608422B2 (ja) | 2014-03-25 | 2015-03-25 | モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10434167B2 (enExample) |
| EP (1) | EP3122380B1 (enExample) |
| JP (1) | JP6608422B2 (enExample) |
| KR (1) | KR102242875B1 (enExample) |
| CN (1) | CN107124869B (enExample) |
| AU (1) | AU2015236106A1 (enExample) |
| CA (1) | CA2943190A1 (enExample) |
| MX (1) | MX2016012168A (enExample) |
| RU (1) | RU2016141622A (enExample) |
| SG (2) | SG11201607396WA (enExample) |
| WO (1) | WO2015148648A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017153993A1 (en) * | 2016-03-09 | 2017-09-14 | Technion Research And Development Foundation Ltd. | Liposomal formulations and methods of using same in agriculture |
| JP6661454B2 (ja) * | 2016-04-21 | 2020-03-11 | 株式会社東海理化電機製作所 | 表示装置、表示板の製造方法 |
| SG10202108075YA (en) * | 2017-04-25 | 2021-09-29 | Adjuvance Technologies Inc | Triterpene saponin analogues |
| US11583578B2 (en) | 2017-04-28 | 2023-02-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery |
| CN107669692B (zh) * | 2017-09-07 | 2020-09-29 | 中国人民解放军第二军医大学 | Mpla在制备电离辐射致肠道损伤防治药物中的应用 |
| KR102755593B1 (ko) * | 2017-09-08 | 2025-01-20 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사포닌을 포함하는 리포솜 제형 및 사용 방법 |
| WO2020243166A1 (en) * | 2019-05-28 | 2020-12-03 | The Regents Of The University Of California | Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens |
| CN110613844B (zh) * | 2019-10-23 | 2024-02-27 | 中国医学科学院生物医学工程研究所 | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 |
| KR20220119085A (ko) | 2019-12-20 | 2022-08-26 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 톨-유사 수용체 (“tlr”) 효능제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| EP3892296A1 (en) * | 2020-04-07 | 2021-10-13 | InnoMedica Holding AG | Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine |
| EP4000603A4 (en) * | 2020-06-30 | 2023-08-09 | Eyegene, Inc. | SAPONIN-INDUCED HEMOLYSIS INHIBITION COMPOSITION CONTAINING A CATIONIC LIPOSOME |
| GB2600468A (en) | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| CN112546233A (zh) * | 2020-12-25 | 2021-03-26 | 常州大学 | 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法 |
| CN114366810B (zh) * | 2022-02-15 | 2024-11-22 | 中国人民解放军陆军军医大学 | 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用 |
| KR20240159001A (ko) * | 2022-03-14 | 2024-11-05 | 화이자 인코포레이티드 | 보조제의 제조 방법 |
| KR20250054810A (ko) | 2022-09-29 | 2025-04-23 | 화이자 인코포레이티드 | Rsv f 단백질 삼량체를 포함하는 면역원성 조성물 |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| CN120475988A (zh) * | 2022-12-13 | 2025-08-12 | 辉瑞公司 | 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法 |
| WO2025057058A1 (en) * | 2023-09-13 | 2025-03-20 | Pfizer Inc. | Methods for producing an adjuvant |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025257712A1 (en) | 2024-06-12 | 2025-12-18 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4302459A (en) | 1980-03-19 | 1981-11-24 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| CN1093255A (zh) * | 1986-06-17 | 1994-10-12 | 恩特雷麦德有限公司 | 抗甾醇疫苗 |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
| US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| PT761231E (pt) * | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
| WO1994014454A1 (en) * | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccines against sterols |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6846489B1 (en) * | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| ATE252372T1 (de) | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| WO1998016201A1 (en) | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| IL130822A (en) | 1996-10-15 | 2005-12-18 | Elan Pharm Inc | N-acyl phosphatidylethanolamine-mediated liposomaldrug delivery |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CN101711278B (zh) * | 2007-03-01 | 2013-08-14 | 美国天主教大学 | 与基质结合的t4噬菌体 |
| GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| WO2012088414A1 (en) * | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
-
2015
- 2015-03-25 WO PCT/US2015/022461 patent/WO2015148648A1/en not_active Ceased
- 2015-03-25 EP EP15716264.5A patent/EP3122380B1/en active Active
- 2015-03-25 AU AU2015236106A patent/AU2015236106A1/en not_active Abandoned
- 2015-03-25 US US15/127,081 patent/US10434167B2/en active Active
- 2015-03-25 CN CN201580026334.9A patent/CN107124869B/zh active Active
- 2015-03-25 MX MX2016012168A patent/MX2016012168A/es unknown
- 2015-03-25 KR KR1020167026025A patent/KR102242875B1/ko active Active
- 2015-03-25 SG SG11201607396WA patent/SG11201607396WA/en unknown
- 2015-03-25 RU RU2016141622A patent/RU2016141622A/ru not_active Application Discontinuation
- 2015-03-25 CA CA2943190A patent/CA2943190A1/en not_active Abandoned
- 2015-03-25 SG SG10201808315UA patent/SG10201808315UA/en unknown
- 2015-03-25 JP JP2017502920A patent/JP6608422B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515889A5 (enExample) | ||
| RU2016141622A (ru) | Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин | |
| US10934328B2 (en) | HIV vaccine formulation | |
| JP2020533340A5 (enExample) | ||
| Stegmann et al. | Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation | |
| JP2013523617A (ja) | Ｈｉｖワクチン | |
| JPH04210925A (ja) | 鼻腔内または吸入投与用ワクチン製剤およびその製造方法 | |
| BR112021012181A2 (pt) | Formulações e métodos de vacinas de norovírus | |
| WO2017102703A1 (en) | Vaccine | |
| AU2015239025B2 (en) | Novel methods for inducing an immune response | |
| Ben‐Yehuda et al. | Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults | |
| Liu et al. | Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing | |
| WO2024209013A1 (en) | Lipid nanoparticle compositions | |
| JP2017511327A5 (enExample) | ||
| US20170165358A1 (en) | Methods for enhancing the immunostimulation potency of aluminum salt-absorbed vaccines | |
| JP2017536823A (ja) | 髄膜炎ｂワクチン | |
| Janitzek et al. | The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration. Vaccines 2021, 9, 131 | |
| KR20250171641A (ko) | 구강 용해 필름 제형의 바이러스 백신 조성물 | |
| CA3027454C (en) | Hiv vaccine formulation | |
| CN109982715A (zh) | 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法 | |
| TW202436326A (zh) | 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者 | |
| JP6026339B2 (ja) | 経皮吸収剤用のリポソーム担体 | |
| EA039968B1 (ru) | Состав вакцины против hiv |